Refine by
Stress Disorder Articles & Analysis
19 news found
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
The formulated product is branded as Mentabinol®, which addresses various psychiatric disorders. Acute THC consumption can trigger paranoid thoughts in vulnerable individuals. ...
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
Amin Kassam, the CEO of Neeka, a true pioneer in novel surgical procedures, neurological disorders, and innovative health solutions, led the creation and development of the Neeka platform. ...
The library of compounds can be selected to target (personalize) the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate (OUD), and cocaine addiction, alcoholism (AUD), post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and ...
Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. www.laviolettelab.com CanaQuest has further enhanced the formulation and delivery format for maximum bioavailability. ...
Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. www.laviolettelab.com CanaQuest has further enhanced the formulation and delivery format for maximum bioavailability. ...
If a woman has previously been diagnosed with panic disorder or obsessive-compulsive disorder, then they are at risk of the disorder reoccurring in the postpartum period. These disorders are also frequently co-morbid with PPD and may worsen the prognosis. Birth related post traumatic stress ...
Our evidence also found that this formulation targeted a specific nuclear cellular receptor involved in anti-inflammatory mechanisms indicating that this formula may also treat inflammatory disorders. “Our CBD-based Mentanine discovery sets the stage for substantially smaller dosages having the desired results compared to other CBD medications,” stated neuroscientist ...
Steven Laviolette, who has decades of research experience focused on novel pharmacotherapies addressing anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder ...
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced it has been awarded the International CBD Life Science R & D Excellence Award 2020 by Global Health & Pharma, United Kingdom, a ...
The Company’s research is focused on the use of cannabinoids for the development of novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest has identified the regulatory pathways to obtain Drug Identification Numbers (DINs) for its two Master ...
Their research focuses on using cannabinoids for the development of novel pharmacotherapies to address anxiety, depression, addiction, schizophrenia and Post Traumatic Stress Disorder (PTSD). Treena Reilkoff, a Trauma Informed Mediator and Facilitator with the CCDRC stated, “We are pleased to have the opportunity to collaborate with CanaQuest. ...
The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD", including addiction.The Company is the industry partner for research and product development with Dr. ...
“These key pharmacological benefits open the door to a host of other peripheral and central nervous system diseases and disorders as well.” KLS-13019 leads Kannalife’s intellectual property portfolio of novel monotherapeutic molecules (“KLS Family”), which have been proven capable of acting as neuroprotective agents and have the potential to treat a ...
"We are thrilled to be a part of this first-of-a-kind therapeutic advancement with our partners at Cerebral Therapeutics, and we hope this is the start of a long partnership that improves the lives of thousands of patients suffering from neurological disorders." The epileptic therapy being evaluated in the ADDRESS trial includes an abdominal implant of the Prometra® II ...
Department of Veterans Affairs indicate that 15 to 20 percent of service men and women currently in combat will return to the United States suffering from symptoms related to combat stress, including post-traumatic stress disorder. While this is difficult for the service member, it is equally challenging for their loved ones. ...
They argued that such symptoms as palpitations, concentration and memory disorders, headaches, fatigue, stress and sleep disorders were the result of EMF exposures. ...